Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: AD Clear all
Enrolling by invitation Not applicable Interventional

Feasibility of Improving Glycemia With Heat Therapy to Prevent AD

NCT06023407
View directory record Official record
Conditions
Healthy Aging, Alzheimer Disease, Metabolic Disease
Interventions
Water Immersion Heat Therapy
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 3, 2026, 11:38 AM EDT
Terminated Phase 1 Interventional

Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)

NCT06673069
View directory record Official record
Conditions
Alzheimer Disease, Down Syndrome
Interventions
ION269
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
35 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Indianapolis, Indiana • Kansas City, Kansas • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

NCT01518374
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
Interventions
Florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,768 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
26
States / cities
Phoenix, Arizona • Sun City, Arizona • Davis, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 3, 2026, 11:38 AM EDT
Recruiting Not applicable Interventional

The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study

NCT05988385
View directory record Official record
Conditions
Obstructive Sleep Apnea, Cognitive Decline
Interventions
Positive airway pressure, Oral appliance therapy, Positional therapy
Device
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
55 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Tucson, Arizona • New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 3, 2026, 11:38 AM EDT
Recruiting No phase listed Observational

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

NCT04455906
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 65 Years
Enrollment
111 participants
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 3, 2026, 11:38 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

TMS for Cognitive Decline in Aging and Preclinical AD

NCT06956300
View directory record Official record
Conditions
Prodromal Alzheimer's Disease, Preclinical Alzheimer's Disease, Healthy Aging, Cognitive Decline
Interventions
Active rTMS, Sham rTMS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 3 Interventional

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

NCT06224192
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab Prefilled Syringe, Rocatinlimab AI
Combination Product
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 100 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
22
States / cities
Bakersfield, California • Long Beach, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Not applicable Interventional Results available

Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV

NCT01434667
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
APOE genotype and Alzheimer's disease risk disclosure, Alzheimer's disease risk disclosure
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 3, 2026, 11:38 AM EDT
Completed No phase listed Observational

EEG/ERP Longitudinal Study in Alzheimer's Disease (AD)

NCT02769234
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ERP/EEG test, Psychometric testing
Procedure
Lead sponsor
Neuronetrix, Inc.
Industry
Eligibility
60 Years to 95 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
West Palm Beach, Florida • Brookline, Massachusetts • Bennington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Stress-induced Scratching in Healthy and AD

NCT04174651
View directory record Official record
Conditions
Healthy, Atopic Dermatitis
Interventions
Trier Social Stress Test (TSST), Landscape Video
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 59 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 3, 2026, 11:38 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects

NCT00612872
View directory record Official record
Conditions
Parkinson Disease, Alzheimer Disease, Healthy Controls, Multiple Sclerosis
Interventions
[123I]CLINDE
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
30 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Sep 3, 2026, 11:38 AM EDT
Not yet recruiting No phase listed Observational

Implementation of AIP Services for Older Adults With AD

NCT07361601
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 3, 2026, 11:38 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents

NCT01843491
View directory record Official record
Conditions
Healthy, Malaria
Interventions
Ad-PfCA
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

NCT00290498
View directory record Official record
Conditions
Lymphoma
Interventions
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone, Methotrexate, Cytarabine, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years to 60 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Sep 3, 2026, 11:38 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Neuroinflammation Imaging in AD

NCT04274998
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteer
Interventions
[18F]NOS, [11C]PBR28
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 3, 2026, 11:38 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

NCT05984784
View directory record Official record
Conditions
Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis, AD
Interventions
Placebo, IMG-007
Drug
Lead sponsor
Inmagene LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Northridge, California • Valencia, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 3, 2026, 11:38 AM EDT
Recruiting Phase 2 Interventional

MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other

NCT05584826
View directory record Official record
Conditions
Cancer, Adjustment Disorders
Interventions
MDMA
Drug
Lead sponsor
Sunstone Medical
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 3, 2026, 11:38 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

R21 Roche: 3-Way Tau Tracers in AD

NCT05464368
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F]RO-948, 18F-MK6240, 18F-GTP1
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 100 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 3, 2026, 11:38 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)

NCT07180147
View directory record Official record
Conditions
Alzheimer Disease (AD), Cardio Vascular Disease, Mild Cognitive Impairment (MCI), Frailty Syndrome, Disability Physical, Hypertension, Metabolic Syndrome (MetS), Healthy Aging, Obesity &Amp; Overweight
Interventions
Not listed
Lead sponsor
Marymount University
Other
Eligibility
50 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)

NCT00914186
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TS022, Vehicle
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
La Jolla, California • San Diego, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Sep 3, 2026, 11:38 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

NCT02612454
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Months to 17 Years
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
40
States / cities
Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

NCT05398445
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Caring for the Caregiver Network

NCT03049501
View directory record Official record
Conditions
Caregivers of Alzheimer's Disease or Memory Problem Patients
Interventions
Caregiving condition, Nutrition condition
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Characterization of Nicotine Exposure and Urge-to-Smoke Following Use of Electronic and Conventional Cigarettes

NCT02210754
View directory record Official record
Conditions
Smoking
Interventions
blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle), blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle), blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle), blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle), blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle), Marlboro Cigarette
Other
Lead sponsor
Lorillard Tobacco Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Sep 3, 2026, 11:38 AM EDT